|Original language||English (US)|
|Number of pages||6|
|Journal||American Journal of Cardiology|
|State||Published - Aug 1 2010|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
In: American Journal of Cardiology, Vol. 106, No. 3, 01.08.2010, p. 442-447.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - AJC editor's consensus
T2 - Rheumatoid arthritis and atherosclerotic cardiovascular disease
AU - Friedewald, Vincent E.
AU - Ganz, Peter
AU - Kremer, Joel M.
AU - Mease, Philip J.
AU - O'Dell, James R.
AU - Pearson, Thomas A.
AU - Ram, C. Venkata S
AU - Ridker, Paul M.
AU - Salmon, Jane E.
AU - Roberts, William C.
N1 - Funding Information: This continuing medical education activity is supported by an educational grant from Amgen, Thousand Oaks, California. Funding Information: Dr. Friedewald has received speaker's honoraria from Novartis, Bridgewater, New Jersey. Dr. Friedewald is a consultant for AstraZeneca, Wilmington, Delaware; and NiCox, Warren Township, New Jersey. Dr. Ganz has received speaker's honoraria from Pfizer, New York, New York. Dr. Kremer has received speaker's honoraria from Amgen; Bristol-Myers Squibb, New York, New York; and Wyeth, Madison, Wisconsin. Dr. Mease has received research grants (investigator), consulting fees, and speaker's honoraria from Abbott Laboratories, Abbott Park, Illinois; Amgen; Biogen Idec, Cambridge, Massachusetts; Bristol-Myers Squibb; Centocor, Horsham, Pennsylvania; Genentech, South San Francisco, California; Roche, Basel, Switzerland; Wyeth; and Pfizer. Dr. Mease has received consulting fees from UCB, Brussels, Belgium. Dr. O'Dell is a consultant for and has received advisory board honoraria from Amgen. Dr. Ridker has received research support from AstraZeneca; Novartis; Pfizer; Roche, Nutley, New Jersey; Sanofi-Aventis, Bridgewater, New Jersey; and Abbott Laboratories. Dr. Ridker has received nonfinancial research support from Amgen. Dr. Ridker is a coinventor on patents held by Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease. Dr. Ridker is a research consultant for Schering-Plough, Kenilworth, New Jersey; Sanofi-Aventis; AstraZeneca; ISIS, Carlsbad, California; Novartis; and Vascular Biogenics, Tel Aviv, Israel. Dr. Salmon is a consultant for Roche; Wyeth; Alexion, Cheshire, Connecticut; Novo Nordisk, Princeton, New Jersey; and Genentech. Dr. Roberts has received speaker's honoraria from AstraZeneca; Merck/Schering-Plough, Whitehouse Station, New Jersey; and Novartis. All other individuals in a position to control content disclosed no relevant financial relationships.
PY - 2010/8/1
Y1 - 2010/8/1
UR - http://www.scopus.com/inward/record.url?scp=77955460323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955460323&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2010.04.005
DO - 10.1016/j.amjcard.2010.04.005
M3 - Article
C2 - 20643261
AN - SCOPUS:77955460323
SN - 0002-9149
VL - 106
SP - 442
EP - 447
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3